Ann: ONJCRI Evaluates Monepantel Anti-Cancer Mechanism, page-54

I do think that we know a little and don’t know a lot.
What we do know is firming up and the opportunity remains solid.

Ref the passed up vet deal: it is not that you have stumbled, it is your determination to pick yourself up and stay true to your belief.

In essence, we now have an opportunity to better define the vet value, so that is exactly what they are doing. A deal is definitely still achievable and it could be with the same or a different major pharma.

We have solid funding for ALS Ph1 trials - while neurological diseases were on our radar for the next period, this amazing support for science and PharmAust came to light post above.

We have pre-clinical CV19 trials due by December (noting risk with CV 19 rampant in EU again) for the final results. I fully expect nothing has stopped preps for organoid and also Ph1 trials. I can’t stress enough this is very complex, very dangerous, very competitive and resource constrained science. And safety is paramount. AMA saying realistic vax date is 2022! So respect the process as it is there to keep us safe for health and for the company commercially.

ONJ has given us some additional grease lightning to shape up against multiple horrific cancers and paving the way for more testing against more cancers and diseases. Oh, and we had a bit of cash grant thrown in for good luck. Grants need applications so we’ll done PharmAust for working on getting that in place too.

The list of patents discussed in the 70 reasons is not the end of the opportunity. It is however a solid list that presents more research than the company could hope to achieve in the near to medium future.

Our IP could be leveraged by another company to progress research under royalty agreements. Who knows.

On that note, I do wonder what is the go with BromAc royalties ... hmmm

adreamer